1 is prospective population-based cohort study
was approved by a dedicated ethics committee overseen by
2 written informed consent to a protocol that
was approved by a local research ethics board and Health
3 is prospective population-based cohort study
was approved by a medical ethics committee overseen by t
4 Materials and Methods The study
was approved by a research ethics committee, and partici
5 The specific recommendations
were approved by all members of the task force and then
6 terials and Methods This retrospective study
was approved by an ethics review board, and the requirem
7 tive analysis of prospectively acquired data
was approved by an institutional ethics committee, and t
8 iduals had died and had brain autopsies that
were approved by board-certified neuropathologists.
9 small-molecule P2Y receptor antagonists have
been approved by drug/medicines agencies.
10 A number of injectable hydrogels
are approved by FDA as surgery sealants, tissue adhesive
11 It has also
been approved by FDA for various orphan diseases for exp
12 ctive therapy with specific probiotic, as it
was approved by Health Canada for the risk reduction of
13 Materials and Methods The study
was approved by institutional animal and human studies c
14 Materials and Methods The study
was approved by institutional review and commpliant with
15 This study
was approved by institutional review board with waivers
16 This study
was approved by institutional review board with waivers
17 This HIPAA-compliant multicenter study
was approved by institutional review boards of participa
18 IPAA-compliant prospective multicenter study
was approved by institutional review boards with written
19 Study cohorts
were approved by local institutional review boards, and
20 60 drugs approved by the FDA (2010-2014), 40
were approved by OHOP.
21 Materials and Methods This prospective study
was approved by our ethics committee, and written inform
22 ility and Accountability Act-compliant study
was approved by our institutional review board with a wa
23 nonalcoholic fatty liver disease (NAFLD) has
been approved by regulatory agencies.
24 sitron emission tomographic (PET) images has
been approved by regulatory authorities for clinical use
25 tor (GLP-1R) agonists reduce food intake and
are approved by the Food and Drug Administration for the
26 numerous local therapies exist, although few
are approved by the Food and Drug Administration.
27 estrogen receptor-positive breast cancer and
are approved by the U.S. Food and Drug Administration (F
28 l devices often undergo modifications, which
are approved by the US Food and Drug Administration (FDA
29 nce slow inactivation of sodium channels and
are approved by the US Food and Drug Administration for
30 Ipilimumab (CTLA-4) and pembrolizumab (PD-1)
are approved by the US Food and Drug Administration for
31 piratory and gastrointestinal pathogens have
been approved by the FDA and are commercially available,
32 to date, less than two-dozen biomarkers have
been approved by the FDA for clinical use.
33 molecule chemokine receptor antagonists have
been approved by the FDA.
34 over 100 small-molecule oncology drugs have
been approved by the FDA.
35 ns characterized with potent inhibitors have
been approved by the Food and Drug Administration (FDA)
36 s recognized as an immunosuppressant and has
been approved by the Food and Drug Administration to tre
37 d and abbreviated new drug applications have
been approved by the Food and Drug Administration.
38 , dalbavancin, and oritavancin have recently
been approved by the U.S. Food and Drug Administration (
39 In addition, resin microspheres have
been approved by the U.S. Food and Drug Administration f
40 The TZD pioglitazone, which has
been approved by the U.S. Food and Drug Administration,
41 Omalizumab, an anti-IgE mAb, has recently
been approved by the US Food and Drug Administration (FD
42 androgen receptor modulators, which have not
been approved by the US Food and Drug Administration (FD
43 ive drugs with new mechanisms of action have
been approved by the US Food and Drug Administration for
44 Five medications have
been approved by the US Food and Drug Administration for
45 e >100 clinical trials, only 2 new drugs had
been approved by the US Food and Drug Administration for
46 The list of kinase inhibitors that have
been approved by the US Food and Drug Administration was
47 ures, and the decline in the number of drugs
being approved by the US Food and Drug Administration ov
48 Nanoliposomal irinotecan
is approved by the FDA for gemcitabine-refractory metast
49 axel) is a microtubule-stabilizing drug that
is approved by the Food and Drug Administration for the
50 Sorafenib
is approved by the US Food and Drug Administration for m
51 r, the effect size is modest (<50%) and none
is approved by the US Food and Drug Administration.
52 e AACR SPGA Committee and the ASCO CaPC) and
was approved by the AACR Boards of Directors on August 6
53 The study
was approved by the animal care and use committee and wa
54 This study
was approved by the animal care and use committee.
55 Materials and Methods This study
was approved by the animal care committee.
56 Materials and Methods The study
was approved by the animal care committee.
57 oup developed this position statement, which
was approved by the ASHG Board in March 2017.
58 This study
was approved by the Cantonal Research Ethics Committee a
59 Each treatment
was approved by the clinical ethics committee.
60 The study
was approved by the Committee for the Protection of Huma
61 ed from all patients, and the study protocol
was approved by the committee on human research.
62 The study
was approved by the Dutch Minister of Health, Welfare an
63 d Methods Design and execution of this study
was approved by the Ethical Committee of Institute for R
64 The study
was approved by the ethical committee of the University
65 terials and Methods This retrospective study
was approved by the ethical review board, and the need t
66 The retrospective study
was approved by the ethics board and did not require inf
67 This study
was approved by the ethics committee at the institution.
68 The study
was approved by the ethics committee for studies in huma
69 Materials and Methods This prospective study
was approved by the ethics committee of the University H
70 This study
was approved by the ethics committee, and all participan
71 Materials and Methods This two-part study
was approved by the ethics committee, and written consen
72 This retrospective case-control study
was approved by the ethics committee, which waived the n
73 Materials and Methods This prospective study
was approved by the ethics review board, and informed co
74 ranscatheter aortic valve replacement (TAVR)
was approved by the Food and Drug Administration (FDA) i
75 gher avidity variant of CTLA4Ig (abatacept),
was approved by the Food and Drug Administration for pro
76 Materials and Methods The protocol
was approved by the French Ethics Committee for Animal E
77 Materials and Methods The study
was approved by the GE Global Research Center Institutio
78 Materials and Methods This prospective study
was approved by the independent ethics committees of Kan
79 Materials and Methods The study
was approved by the institutional animal care and use co
80 Materials and Methods This study
was approved by the Institutional Animal Care and Use Co
81 The study
was approved by the Institutional Animal Care and Use Co
82 Materials and Methods The animal protocol
was approved by the institutional animal care and use co
83 Materials and Methods This prospective study
was approved by the Institutional Animal Care and Use Co
84 Materials and Methods The study
was approved by the institutional animal care and use co
85 Materials and Methods This study
was approved by the institutional animal care and use co
86 This study
was approved by the institutional animal care committee.
87 The protocol for animal experiments
was approved by the institutional animal care committee.
88 terials and Methods This retrospective study
was approved by the institutional board review; written
89 ed from all patients, and the study protocol
was approved by the institutional committee on human res
90 ed from all patients, and the study protocol
was approved by the institutional ethical committee.
91 The study protocol
was approved by the institutional ethics committee of th
92 The research
was approved by the institutional ethics committee revie
93 This retrospective study
was approved by the institutional ethics committee, and
94 This prospective study
was approved by the institutional ethics committee, and
95 terials and Methods This retrospective study
was approved by the institutional ethics committee.
96 This prospective study
was approved by the institutional ethics committee.
97 MATERIALS AND METHODS This prospective study
was approved by the institutional ethics committee; info
98 c resonance (MR) imaging substudy; the study
was approved by the institutional research board, and wr
99 Materials and Methods This research
was approved by the institutional review board (IRB) and
100 In this HEBE trial substudy, which
was approved by the institutional review board (trial re
101 Materials and Methods This study
was approved by the institutional review board and all p
102 This study
was approved by the institutional review board and by na
103 Materials and Methods This study
was approved by the institutional review board and compl
104 This prospective study
was approved by the institutional review board and compl
105 This study
was approved by the institutional review board and compl
106 Materials and Methods This study
was approved by the institutional review board and compl
107 This study
was approved by the institutional review board and compl
108 The study
was approved by the institutional review board and compl
109 This retrospective analysis
was approved by the institutional review board and compl
110 The study
was approved by the institutional review board and compl
111 rials and Methods This cross-sectional study
was approved by the institutional review board and compl
112 Materials and Methods This study
was approved by the institutional review board and compl
113 terials and Methods This retrospective study
was approved by the institutional review board and compl
114 hods This single-center, retrospective study
was approved by the institutional review board and compl
115 terials and Methods This retrospective study
was approved by the institutional review board and compl
116 The research
was approved by the institutional review board and confo
117 Materials and Methods The study
was approved by the institutional review board and local
118 The study
was approved by the institutional review board and patie
119 rials and Methods Work with human stem cells
was approved by the institutional review board and the s
120 This prospective single-center cohort study
was approved by the institutional review board and was c
121 This study
was approved by the institutional review board and was c
122 This retrospective study
was approved by the institutional review board and was c
123 The study
was approved by the institutional review board and was H
124 Materials and Methods The study
was approved by the institutional review board and writt
125 The NLST
was approved by the institutional review board at each p
126 This HIPAA-compliant study
was approved by the institutional review board for resea
127 This retrospective HIPAA-compliant study
was approved by the institutional review board of Duke U
128 This study protocol
was approved by the institutional review board of each c
129 ods This HIPAA-compliant retrospective study
was approved by the institutional review board of the Un
130 Materials and Methods The study
was approved by the Institutional Review Board of the Un
131 terials and Methods This retrospective study
was approved by the institutional review board of three
132 This HIPAA-compliant study
was approved by the institutional review board under an
133 This retrospective study
was approved by the institutional review board with pati
134 This HIPAA-compliant study
was approved by the institutional review board with waiv
135 Materials and Methods This study
was approved by the institutional review board, and all
136 The study
was approved by the institutional review board, and all
137 This study
was approved by the institutional review board, and all
138 This study
was approved by the institutional review board, and all
139 This study
was approved by the institutional review board, and all
140 The study
was approved by the institutional review board, and all
141 Materials and Methods This study
was approved by the institutional review board, and all
142 This retrospective study
was approved by the institutional review board, and info
143 The study
was approved by the institutional review board, and info
144 This prospective study
was approved by the institutional review board, and info
145 terials and Methods This retrospective study
was approved by the institutional review board, and info
146 This single-center retrospective study
was approved by the institutional review board, and the
147 ods This HIPAA-compliant retrospective study
was approved by the institutional review board, and the
148 ods This HIPAA-compliant retrospective study
was approved by the institutional review board, and the
149 This retrospective study
was approved by the institutional review board, and the
150 This HIPAA-compliant study
was approved by the institutional review board, and the
151 This HIPAA-compliant retrospective study
was approved by the institutional review board, and the
152 This retrospective study
was approved by the institutional review board, and the
153 terials and Methods This retrospective study
was approved by the institutional review board, and the
154 Materials and Methods This study
was approved by the institutional review board, and writ
155 This study
was approved by the institutional review board, and writ
156 SHIP
was approved by the institutional review board, and writ
157 This study
was approved by the institutional review board, and writ
158 This HIPAA-compliant study
was approved by the institutional review board, and writ
159 This retrospective study
was approved by the institutional review board, and writ
160 terials and Methods This retrospective study
was approved by the institutional review board, which wa
161 t retrospective, single-institution analysis
was approved by the institutional review board, with wai
162 This HIPAA-compliant study
was approved by the institutional review board, with wai
163 This study
was approved by the institutional review board.
164 This retrospective study
was approved by the institutional review board.
165 Materials and Methods The study
was approved by the institutional review board.
166 rials and Methods This HIPAA-compliant study
was approved by the institutional review board.
167 terials and Methods This retrospective study
was approved by the institutional review board.
168 Materials and Methods This prospective study
was approved by the institutional review board.
169 This retrospective study
was approved by the institutional review board.
170 This retrospective study
was approved by the institutional review board.
171 This HIPAA-compliant study
was approved by the institutional review board.
172 This HIPAA-compliant prospective study
was approved by the institutional review board.
173 pliant study with waiver of informed consent
was approved by the institutional review board.
174 gave written informed consent, and the study
was approved by the institutional review board.
175 Materials and Methods This study
was approved by the institutional review board.
176 thods This prospective HIPAA-compliant study
was approved by the institutional review board.
177 ective, single-center, HIPAA-compliant study
was approved by the institutional review board.
178 rials and Methods This HIPAA-compliant study
was approved by the institutional review board.
179 compliant, single-center retrospective study
was approved by the institutional review board.
180 Methods This prospective case-control study
was approved by the institutional review board.
181 Materials and Methods This prospective study
was approved by the institutional review board.
182 terials and Methods This retrospective study
was approved by the institutional review board.
183 s This prospective and HIPAA-compliant study
was approved by the institutional review board.
184 center retrospective study and meta-analysis
was approved by the institutional review board.
185 This HIPAA-compliant retrospective study
was approved by the institutional review board.
186 This study
was approved by the institutional review board; all indi
187 terials and Methods This retrospective study
was approved by the institutional review board; informed
188 thods This prospective cross-sectional study
was approved by the institutional review board; informed
189 ods This HIPAA-compliant retrospective study
was approved by the institutional review board; the requ
190 Materials and Methods This prospective study
was approved by the institutional review boards and comp
191 Materials and Methods The study protocol
was approved by the institutional review boards and was
192 The HIPAA-compliant protocol
was approved by the institutional review boards of all p
193 The study
was approved by the institutional review boards of the c
194 als and Methods The HIPAA-compliant protocol
was approved by the institutional review boards of the p
195 thods This prospective cross-sectional study
was approved by the institutional review boards, and all
196 thods This HIPAA-compliant prospective study
was approved by the institutional review boards, and wri
197 This study
was approved by the institutional review boards.
198 The 7-T MR imaging protocol
was approved by the Italian Ministry of Health and by th
199 The study
was approved by the Johns Hopkins institutional review b
200 The trial protocol
was approved by the Local Ethical Committee of the Kirik
201 Materials and Methods This study
was approved by the local ethical committee, and written
202 This study
was approved by the local ethical committee, and written
203 Materials and Methods This prospective study
was approved by the local ethical committee.
204 This study
was approved by the local ethical committees on human st
205 This study
was approved by the local ethical committees on human st
206 rospective cohort study were included, which
was approved by the local ethics board and written infor
207 nance (MR) imaging studies from 2008 to 2015
was approved by the local ethics board.
208 and Methods Retrospective evaluation of data
was approved by the local ethics committee and informed
209 Materials and Methods The study
was approved by the local ethics committee and the local
210 Methods This prospective case-control study
was approved by the local ethics committee and the resea
211 Materials and Methods This study
was approved by the local ethics committee at all partic
212 Retrospective data evaluation
was approved by the local ethics committee of the Univer
213 Materials and Methods The study
was approved by the local Ethics Committee, and all pati
214 Materials and Methods The study
was approved by the local ethics committee, and all subj
215 The study
was approved by the local ethics committee, and all subj
216 ls and Methods Retrospective data evaluation
was approved by the local ethics committee, and the requ
217 The study
was approved by the local ethics committee, and written
218 This retrospective HIPAA-compliant study
was approved by the local ethics committee, and written
219 This retrospective case-control study
was approved by the local ethics committee, and written
220 This study
was approved by the local ethics committee, and written
221 Materials and Methods This in vivo study
was approved by the local ethics committee, and written
222 nterpretation of prospectively acquired data
was approved by the local ethics committee.
223 Materials and Methods The study protocol
was approved by the local ethics committee.
224 omplied with the Declaration of Helsinki and
was approved by the local ethics committee.
225 The study
was approved by the local ethics committee.
226 Materials and Methods The study
was approved by the local ethics committee.
227 omplied with the Declaration of Helsinki and
was approved by the local ethics committee.
228 This study
was approved by the local ethics committees on human stu
229 Materials and Methods This prospective study
was approved by the local ethics committees, and written
230 This study
was approved by the local ethics committees; informed co
231 The protocol
was approved by the local institutional review board and
232 This study
was approved by the local institutional review board and
233 The protocol
was approved by the local institutional review board and
234 This prospective study
was approved by the local institutional review board, an
235 Methods This retrospective comparative study
was approved by the local institutional review board.
236 The study
was approved by the local institutional review board.
237 This retrospective study
was approved by the local institutional review board; in
238 Materials and Methods This study
was approved by the local medical ethical committees of
239 Materials and Methods The study
was approved by the local research ethics committee, and
240 aterials and Methods This case-control study
was approved by the local research ethics committee.
241 This study
was approved by the local research ethics committee.
242 gave written informed consent and the study
was approved by the local research ethics committee.
243 ials and Methods This retrospective analysis
was approved by the local research ethics committee.
244 Materials and Methods The study
was approved by the local review board (NL42888.029.13).
245 The study
was approved by the National Research Ethical Committee,
246 Materials and Methods This study
was approved by the national research ethics committee a
247 The study
was approved by the national research ethics committee,
248 METHODS AND This study
was approved by the National Research Ethics Service Com
249 Materials and Methods The study
was approved by the National Research Ethics Service Com
250 This study
was approved by the Partners in Health/Zanmi Lasante Res
251 The experimental protocol
was approved by the regional animal ethics committee.
252 The study
was approved by the regional ethics committee, and all p
253 This prospective study
was approved by the regional ethics committee.
254 rials and Methods This HIPAA-compliant study
was approved by the regional ethics committee.
255 Left atrial appendage closure (LAAC)
was approved by the U.S. Food and Drug Administration (F
256 id Capture 2 human papillomavirus (HPV) test
was approved by the U.S. Food and Drug Administration (F
257 d written informed consent, and the protocol
was approved by the university institutional review boar
258 written informed consent; the study protocol
was approved by the university institutional review boar
259 This study
was approved by the University of Otago Human Ethics Com
260 This study
was approved by the University of Toronto Research Ethic
261 The study
was approved by the University's research ethics committ
262 ant neoplasms; trametinib dimethyl sulfoxide
was approved by the US Food and Drug Administration for
263 ranscatheter aortic valve replacement (TAVR)
was approved by the US Food and Drug Administration for
264 ant tissue plasminogen activator (alteplase)
was approved by the US Food and Drug Administration in 1
265 The study
was approved by the Walter Reed National Military Medica
266 This study
was approved by the Walter Reed National Military Medica
267 oversight committee, and animal experiments
were approved by the administrative panel on laboratory
268 Materials and Methods All animal experiments
were approved by the animal care and use committee and a
269 Materials and Methods All procedures
were approved by the Animal Care and Use Committee and c
270 All protocols
were approved by the Animal Care Committee in accordance
271 (broth, 1 to 4 mug/ml; agar, 1 to 8 mug/ml)
were approved by the Clinical and Laboratory Standards I
272 disk diffusion (30/20-mug disk) test methods
were approved by the CLSI Subcommittee on Antimicrobial
273 and MIC QC ranges established in this study
were approved by the CLSI Subcommittee on Antimicrobial
274 All biological mesh devices
were approved by the FDA based on substantial equivalenc
275 Animal studies
were approved by the Institutional Administrative Panel
276 Experiments involving animals
were approved by the Institutional Administrative Panel
277 Animal model studies
were approved by the institutional Animal Care and Use C
278 Materials and Methods All experiments
were approved by the institutional animal care and use c
279 All procedures
were approved by the institutional animal care and use c
280 Materials and Methods All animal procedures
were approved by the institutional Animal Care and Use C
281 Materials and Methods All animal studies
were approved by the institutional animal care and use c
282 Materials and Methods All studies
were approved by the institutional animal care and use c
283 Materials and Methods Experiments
were approved by the institutional animal care and use c
284 Materials and Methods Animal experiments
were approved by the institutional animal care and use c
285 All animal experiments
were approved by the institutional animal care committee
286 Materials and Methods The procedures
were approved by the institutional animal care committee
287 The animal studies
were approved by the local animal ethics committee.
288 Materials and Methods The animal experiments
were approved by the local ethics committee.
289 Materials and Methods All experiments
were approved by the local institutional review board an
290 Materials and Methods Protocols
were approved by the office of biologic safety and insti
291 rence to the Swiss Animal Protection law and
were approved by the regional veterinary office.
292 Eight new antibiotics
were approved by the U.S. Food and Drug Administration (
293 Materials and Methods All rat experiments
were approved by the University of Washington Institutio
294 For oncology drugs that
were approved by the US Food and Drug Administration (FD
295 4 patented, injectable anticancer drugs that
were approved by the US Food and Drug Administration bet
296 Romidepsin and pralatrexate
were approved by the US Food and Drug Administration for
297 Materials and Methods All procedures
were approved by the Weizmann Institutional Animal Care
298 This study
was approved by three institutional review boards and wa
299 onucleotide-based drug (nusinersen/Spinraza)
was approved by US Food and Drug Administration (FDA) in
300 as obtained for all procedures and the study
was approved by Western University's Health Sciences Res